Primary hyperoxaluria type 1: Clinical, genetic, and evolutionary characteristics in Tunisian children


Abir Boussetta
Rihab Fatnassi
Manel Jellouli
Rym Maamouri
Ridha Mrad
Tahar Gargah
Asma Omezzine


Introduction: There are three types of primary hyperoxaluria, with type 1 considered the most severe.

Aim: To analyze the clinical, genetic, and evolutionary characteristics of type 1 primary hyperoxaluria with pediatric onset.

Methods: This was a retrospective, descriptive study that included Tunisian children under the age of 18 at the time of diagnosis over a period of 25 years (January 1, 1996, to December 31, 2022).

Results: Thirty-five patients were included, with a mean age of 4.1 years. The most common presenting circumstances of the disease were nephrolithiasis and end-stage renal failure. The average serum creatinine level was 225.42 µmol/l. Five mutations were identified, with the p.Ile244Thr mutation being the most prevalent. Nephrocalcinosis, surgical intervention, and a creatinine level ≥57 µmol/l were predictive of progression to end-stage renal failure. The infantile form was predictive of mortality.

Conclusions: Screening for the disease would improve the prognosis of this condition.


Children, Primary hyperoxaluria, AGXT gene, Chronic kidney failure, Mortality



  1. Ben-Shalom E, Frishberg Y. Primary hyperoxalurias: diagnosis and treatment. Pediatr Nephrol. 2015;30(10):1781‑91.
  2. Bouzidi H, Majdoub A, Daudon M, Najjar MF. Primary hyperoxaluria: a review. Nephrol Ther. 2016;12(6):431‑6.
  3. Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol. 2012;8(8):467‑75.
  4. Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P. Primary hyperoxaluria. Int J Nephrol. 2011;2011:864580.
  5. Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369(7):649‑58.
  6. Meriam H, Bettaieb A, Kaaroud H, Ben Hamida F, Gargeh T, Mrad R, et al. Primary Hyperoxaluria Type 1: Clinical, Paraclinical, and Evolutionary Aspects in Adults from One Nephrology Center. Int J Nephrol. 2023;2023:2874414.
  7. Cochat P, Hulton S, Acquaviva C, Danpure CJ, Daudon M, de Marchi M, et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012;27:1729-36.
  8. Garrelfs SF, Rumsby G, Peters-Sengers H, Erger F, Groothoff JW, Beck BB, et al. Patients with primary hyper- oxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int. 2019;96:1389-99.
  9. Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009;75(12):1264‑71.
  10. Hoppe B, Martin-Higueras C. Improving Treatment Options for Primary Hyperoxaluria. Drugs. 2022;82(10):1077-1094.
  11. Cochat P, Fargue S, Bacchetta J, Bertholet-Thomas A, Sabot JF, et al. Primary hyperoxaluria]. Nephrol Ther. 2011;7(4):249-59.
  12. Fadel FI, Kotb MA, Abdel Mawla MA, Hasanin RM, Salem AM, Fathallah MG,rimary hyperoxaluria type 1 in children: Clinical classification, renal replacement therapy, and outcome in a single centre experience. Ther Apher Dial. 2022;26(1):162-170.
  13. Pietrement C, Allain-Launay E, Bacchetta J, Bertholet-Thomas A, Dubourg L, Harambat J, et al. Diagnostic et prise en charge de la maladie rénale chronique de l’enfant : recommandations de la Société de néphrologie pédiatrique (SNP). Arch Pédiatr. 2016;23(11):1191‑200.
  14. Chemli J, Abdennabi H, Zorgati M, Abdelhak S, Nabli N, Abroug S, et al. Primary hyperoxaluria in children in central Tunisia. Tunis Med. 2007;85(6):513‑8.
  15. Mandrile G, Pelle A, Sciannameo V, Benetti E, D’Alessandro MM, Emma F, et al. Primary hyperoxaluria in Italy: the past 30 years and the near future of a (not so) rare disease. J Nephrol. 2022;35(3):841‑50.
  16. Almardini RI, Alfarah MG, Salaita GM. The clinical pattern of primary hyperoxaluria in pediatric patient at Queen Rania Abdulla children hospital. Arab J Nephrol Transplant. 2014;7(2):119‑23.
  17. Kamoun A, Daudon M, Zghal A, Lasram L, Ben Maiz H, Belkahia C, et al. Hyperoxalurie primitive: l’expérience tunisienne à propos de 24 cas. Néphrologie. 1997;18(2):59‑64.
  18. Sikora P, Zaniew M, Grenda R, Jobs K, Rubik J, Zawadzki J, et al. Still diagnosed too late and under-recognized? The first comprehensive report on primary hyperoxaluria in Poland. Pol Arch Intern Med. 2020;130(12):1053‑63.
  19. Boussetta A, Karray A, Abida N, Jellouli M, Gargah T. Monogenic urinary lithiasis in Tunisian children: 25 years' experience of a referral center. Tunis Med. 2022;100(5):410-415.
  20. Alfadhel M, Umair M, Alghamdi MA, Al Fakeeh K, Al Qahtani AT, Farahat A, et al. Clinical and molecular characterization of a large primary hyperoxaluria cohort from Saudi Arabia: a retrospective study. Pediatr Nephrol [En ligne]. Nov 2022 [Consulté le 25 jan 2023]; [10 pages]. Disponible à l’URL:
  21. Hoppe B, Latta K, Von Schnakenburg C, Kemper MJ. Primary hyperoxaluria – the German experience. Am J Nephrol. 2005;25(3):276‑81.
  22. Mandrile G, Beck B, Acquaviva C, Rumsby G, Deesker L, Garrelfs S, et al. Genetic assessment in primary hyperoxaluria: why it matters. Pediatr Nephrol. 2023;38(3):625‑34.
  23. Soliman NA, Elmonem MA, Abdelrahman SM, Nabhan MM, Fahmy YA, Cogal A, et al. Clinical and molecular characterization of primary hyperoxaluria in Egypt. Sci Rep. 2022;12(1):15886.
  24. Rhuma NR, Fituri OA, Sabei LT. Mutational analysis of AGXT gene in Libyan children with primary hyperoxaluria type 1 at Tripoli children hospital. Saudi J Kidney Dis Transpl. 2018;29(1):30‑8.
  25. Boualla L, Tajir M, Oulahiane N, Lyahyai J, Laarabi FZ, Chafai Elalaoui S, et al. AGXT gene mutations and prevalence of primary hyperoxaluria type 1 in Moroccan population. Genet Test Mol Biomarkers. 2015;19(11):623‑8.
  26. Mbarek IB, Abroug S, Omezzine A, Zellama D, Achour A, Harbi A, et al. Selected AGXT gene mutations analysis provides a genetic diagnosis in 28% of Tunisian patients with primary hyperoxaluria. BMC Nephrol. 2011;12:25.
  27. Nagara M, Tiar A, Ben Halim N, Ben Rhouma F, Messaoud O, Bouyacoub Y, et al. Mutation spectrum of primary hyperoxaluria type 1 in Tunisia: implication for diagnosis in North Africa. Gene. 2013;527(1):316‑20.
  28. Medina PG, Román LE. Importance of assessing compliance with conservative treatment of primary hyperoxaluria Type 1: a case report of a patient with I244T/c.969-3C>G mutation. Perm J. 2020;24:19.
  29. Groothoff JW, Metry E, Deesker L, Garrelfs S, Acquaviva C, Almardini R, et al. Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nat Rev Nephrol. 2023;19(3):194-211.
  30. Harambat J, Van Stralen KJ, Espinosa L, Groothoff JW, Hulton SA, Cerkauskiene R, et al. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol. 2012;7(3):458‑65.
  31. Soliman NA, Nabhan MM, Abdelrahman SM, Abdelaziz H, Helmy R, Ghanim K, et al. Clinical spectrum of primary hyperoxaluria type 1: experience of a tertiary center. Nephrol Ther. 2017;13:176-82.
  32. Groothoff JW, Metry E, Deesker L, Garrelfs S, Acquaviva C, Almardini R, et al. Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nat Rev Nephrol. 2023;19(3):194-211.
  33. Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P,Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021;384(13):1216-1226.